Tuesday, August 25, 2026 Home
Startup Atlas · Pharmaceuticals

Alkem Laboratories Ltd Sector Top 20

Pharmaceutical company operating in the generic and speciality pharmaceutical sector with a footprint in 40 countries.

UndisclosedTotal funding (tracked)
0Funding rounds
Last round
Publicly listed · NSE:ALKEM
₹5,343.25 -1.01% BSE, as of 24 Aug 26 | 12:46

Valuation

P/E18.12
P/E · TTM29.88
P/B4.37

Returns

ROE16.60%
ROCE18.95%

Per share

EPS294.83
Book value1,218.48

Growth · year on year

Sales+9.65%
Profit+4.57%

Ownership

Promoter holding49.70%

Price and ratios are compiled from the exchange and third-party market data, cached and refreshed through the day — they are not Atlas facts and are not investment advice. Where a ratio is computed on more than one basis (for example standalone versus trailing-twelve-month), each is shown separately rather than averaged into a single number.

61/100
Solid Atlas Score — computed from 7 published figures
How this score is calculated
Measure Value Scores Source
P/E
What the market pays for each rupee of earnings. Lower is cheaper — but a low P/E can also mean the market expects earnings to fall.
Computed on a different basis this reads 29.88, which would score 50/100. Scored on the figure shown.
18.12 75/100 BSE
P/B
Price against book value. Most meaningful for banks and asset-heavy businesses; software and consumer brands trade high here for good reasons.
4.37 50/100 Market data
ROE
Return on equity — profit generated per rupee of shareholder capital. Sustained high ROE is the clearest single marker of a good business.
16.60 75/100 Market data
ROCE
Return on capital employed — the same idea including debt, so it is harder to flatter with leverage.
18.95 75/100 Market data
Profit growth
Year-on-year growth in profit. Weighted above sales growth because profitable growth is the harder thing to do.
4.57 25/100 Market data
Sales growth
Year-on-year growth in revenue.
9.65 50/100 Market data
Promoter holding
How much of the company its founders and controlling group still own. Higher usually means their money moves with yours.
49.70 75/100 Market data

The Atlas Score is our own arithmetic on the published figures above — nothing is hidden and nothing is bought in. It weighs quality and growth at 30% each, valuation at 25% and ownership at 15%, scoring each measure against fixed bands. Growth blends third-party market data with the fiscal-year figures we file and cite ourselves, so a company we have researched more deeply scores on richer evidence. A measure we could not fetch is left out of the average rather than counted as a zero. It is a summary of the numbers, not a recommendation, not a price target, and not advice about your circumstances.

View Alkem Laboratories Ltd's live share price on Google Finance ↗

Alkem Laboratories Ltd: Funding Rounds

No funding rounds tracked for Alkem Laboratories Ltd yet.

News on Alkem Laboratories Ltd

No coverage of Alkem Laboratories Ltd linked yet.

L Litmus · by Lapaas

Got an idea like this one? Validate it with the same 9-block framework, free.

Start Free Validation

FAQs on Alkem Laboratories Ltd

What does Alkem Laboratories Ltd do?

Pharmaceutical company operating in the generic and speciality pharmaceutical sector with a footprint in 40 countries.

Sources & corrections. Every fact on this page is compiled from cited public sources — follow the "source" links beside each entry. Profile sources: www.bseindia.com www.alkemlabs.com · Last verified 24 Aug 2026. · Report a correction